Race Oncology Ltd

RAC

Race Oncology Ltd. is a clinical stage biotechnology company, which engages in the discovery and development of a novel approach to cancer treatment and cardio protection. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. The firm is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. The company is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.

Radiopharm Theranostics Limited

RAD

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The company has a pipeline of differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the universities and institutes around the world. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including lung, pancreas and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

Regener8 Resources NL

R8R

Regener8 Resources NL engages in raising seed capital to fund the company's activities. The company is headquartered in Perth, Western Australia. The company went IPO on 2022-07-08. The company operates in two segments: the Kookynie Gold Project and the East Ponton Future Metals Project. The Kookynie Gold Project comprises of one exploration license and eight prospecting licenses located in the Kookynie region in Western Australia's Goldfields region. The Kookynie Gold Project is located in the northern Goldfields region of WA, covering an area of approximately 15 square kilometers (km2) within the North Coolgardie Mineral Field. The Project is approximately 155 kilometers (km) north of Kalgoorlie and 55 km south of Leonora Township. Its projects include Niagara West, Niagara East, Niagara North, and the Reach prospect. The East Ponton Future Metals Project consists of the Grasshopper and Seven Sisters prospects located approximately 220 km east of Kalgoorlie, WA. The tenement package is prospective for Rare Earth Elements (REE), Lithium, and Gold.